Jim Cramer says the economy is headed for a soft landing

Jim Cramer says the economy is headed for a soft landing


Cramer says he's betting with Fed Chairman Jerome Powell

CNBC’s Jim Cramer on Monday told investors that he thinks the Federal Reserve will steer the economy to a soft landing.

“The only outcome is a soft landing for the economy, which means it’s foolish to sell now since you’ll only end up buying back those same stocks at higher levels in order to get in ahead of the turn in 2024,” he said.

related investing news

Markets may be taking the wrong read from January's shocking jobs report

CNBC Pro

Stocks fell on Monday as investors grew cautious of rising bond yields. Treasury bond yields gained, with the 10-year yield up by nearly 11 basis points at 3.64% and the 2-year yield rising about 18 basis points to 4.48%. Yields and prices move inversely.

Cramer, who has said in recent weeks that the market is in bull mode, doubled down on his stance despite the worrying moves in bond yields.

“I’d even go as far as to say that the bond market’s wrong … long-term bond yields are lower than short[-term] ones, signaling a recession, and I think that’s simply incorrect,” he said.

Cramer added that a key reason he doesn’t expect a hard landing is the stronger-than-expected January jobs report. Nonfarm payrolls grew by 517,000 last month, far surpassing the Dow Jones estimate of 187,000 and December’s gain of 260,000.

“That number unequivocally supports the notion of a soft landing. You simply can’t get a hard landing when you’re seeing this much job creation,” he said.

Jim Cramer says the economy is headed for a soft landing

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

Real estate could be the big winner in the private credit exodus
Business

Real estate could be the big winner in the private credit exodus

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Barely […]

Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More